EP2575812A2 - Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid - Google Patents

Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid

Info

Publication number
EP2575812A2
EP2575812A2 EP11790098.5A EP11790098A EP2575812A2 EP 2575812 A2 EP2575812 A2 EP 2575812A2 EP 11790098 A EP11790098 A EP 11790098A EP 2575812 A2 EP2575812 A2 EP 2575812A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition according
cefpodoxime proxetil
clavulanic acid
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11790098.5A
Other languages
German (de)
French (fr)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2575812A2 publication Critical patent/EP2575812A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to pharmaceutical compositions comprising cefpodoxime proxetil and clavulanic acid and/or derivatives thereof as the active agents.
  • Cefpodoxime proxetil (formula I), chemical name of which is pivaloyloxymethyl 7-[2-(2- amino-thiazole-4-yl]-2-(syn)-methoxyimino-acetamido]-3-methoxymethyl-3-cefem-4- carboxylate, was first disclosed in the patent numbered EP0049118.
  • Clavulanic acid is a beta-lactamase inhibitor illustrated in Formula 2.
  • Clavulanic acid and derivatives thereof are known as the beta-lactamase inhibitors which withstand the beta-lactamase-originated resistance mechanism by suppressing the activity of beta-lactamase enzymes.
  • EP0593573 comprises a formulation relating to suspension forms of beta-lactam antibiotics and beta lactamase inhibitors.
  • suspension forms are not preferred much as they have the potential of high and/or uncontrolled dose intake; there appear problems in their physical and chemical stability; they have high manufacture costs and they cause problems in use and carrying.
  • the inventors have aimed to develop stable oral pharmaceutical formulations which comprise cefpodoxime proxetil and clavulanic acid derivatives together and eliminate the low solubility and gelling problems of cefpodoxime.
  • the present invention relates to stable pharmaceutical compositions with good solubility characteristics in which cefpodoxime proxetil and clavulanic acid derivatives are formulated together.
  • Said pharmaceutical composition is characterized by comprising 20% diluent at maximum in addition to cefpodoxim proxetil and clavulanic acid derivatives. It has surprisingly been seen that solid dosage forms which comprise the active agent cefpodoxime proxetil having rather low water solubility and are formulated by the formulation of the present invention have better solubility.
  • the pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid derivatives in combination comprises a diluent in the range of 20% or less, preferably in the range of 2-15%, more preferably in the range of 4-8%.
  • Cefpodoxime proxetil that can be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free base form and/or a combination thereof.
  • Clavulanic acid that can be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free base form and/or a combination thereof.
  • Potassium clavulanate is preferably used in the present invention.
  • the formulation of the present invention can comprise various excipients such as, but not limited to, glidants, lubricants, disintegrants, diluents, surfactants and optionally coating agents.
  • the diluent that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
  • starch is used as the diluent in the pharmaceutical composition of the present invention.
  • the inventors have found that the ratio of cefpodoxime proxetil to the diluent is a factor affecting the dissolution of formulations comprising cefpodoxime proxetil and clavulanic acid or its derivatives. According to this, dissolution tests indicated that dissolution of cefpodoxime proxetil is at the desired level in the case that the ratio of cefpodoxime proxetil to the diluent is in the range of 10:1 to 1 :1, preferably in the range of 8:1 to 2:1, more preferably in the range of 6: 1 to 4: 1.
  • compositions comprising cefpodoxime proxetil and clavulanic acid in which the ratio of cefpodoxime proxetil to the diluent is in the range of 10:1 to 1 :1, preferably in the range of 8:1 to 2:1, more preferably in the range of 6: 1 to 4: 1.
  • the glidant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or combinations thereof.
  • silicon dioxide or talc or a combination thereof is used as the glidant in the pharmaceutical composition of the present invention.
  • the inventors have found that use of a combination composed of talc and silicon dioxide yields more successful results in preventing antistatic adhesion. As a result of the studies they conducted, they have found that successful results are obtained in the case that the ratio of talc to silicon dioxide is in the range of 5:1 to 1:5, preferably in the range of 3:1 to 1 :3, more preferably 1:1.
  • compositions composed of talc and silicon dioxide as the glidant.
  • the present invention is pharmaceutical compositions comprising cefpodoxime proxetil and clavulanic acid or its derivatives which comprise a glidant composition wherein the ratio of talc to silicon dioxide is in the range of 5:1 to 1 :5, preferably in the range of 3 : 1 to 1 :3, more preferably 1 :1.
  • compositions comprising cefpodoxime proxetil and clavulanic acid or its derivatives which include 0,6% talc and/or silicon dioxide at minimum in proportion to unit dose weight.
  • the lubricant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyoxyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or combinations thereof.
  • magnesium stearate is used as the lubricant in the pharmaceutical composition of the present invention.
  • the disintegrant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose calcium, carboxymethyl cellululose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropylcellulose, methyl cellulose, povidone, magnesium aluminum silicate, starch or combinations thereof.
  • croscarmellose sodium or microcrystalline cellulose or a combination thereof is used as the disintegrant in the formulation of the present invention.
  • the surfactant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising docusate sodium, sorbitan esters, cetrimide and sodium lauryl sulfate.
  • sodium lauryl sulfate is preferably used as the surfactant.
  • the pharmaceutical composition of the present invention can comprise 20-800 mg cefpodoxime proxetil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
  • the pharmaceutical composition of the present invention can comprise 50-500 mg clavulanic acid or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
  • Clavulanic acid and its derivatives are extremely susceptible to moisture.
  • potassium clavulanate in the pharmaceutical composition is preferably used with a humectant in the ratio of 1 : 1.
  • colloidal silica for instance colloidal silica anhydrous, for example Aerosil® 200, magnesium trisilicate, cellulose powder, Cabosil®, magnesium oxide, calcium silicate, Syloid®, starch, microcrystalline cellulose, talc can be used as the humectant.
  • potassium clavulanate is used with microcrystalline cellulose preferably in the ratio of 1 : 1.
  • the pharmaceutical composition of the present invention can comprise 5-60% cefpodoxime proxetil in proportion to total weight of unit dose or pharmaceutically acceptable solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms thereof.
  • the pharmaceutical composition of the present invention can comprise 5-50% clavulanic acid in proportion to total weight of unit dose or pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
  • the pharmaceutical composition of the present invention can comprise 5-60% cefpodoxime proxetil; 5-50% potassium clavulanate; 0,5-5% glidant; 0,1-5% lubricant; 0-25% disintegrant and/or disintegrants; 0,5-20% diluent; 0,1-5% surfactant and optionally coating agent of 1-5% of the core weight.
  • the pharmaceutical composition comprising cefpodoxim proxetil and clavulanic acid prepared according to the present invention can be in conventional tablet, film coated tablet, sachet or capsule form.
  • the present invention relates to processes for preparation of pharmaceutical compositions comprising pharmaceutically acceptable excipients in addition to cefpodoxime proxetil and clavulanic acid or its derivatives as the active agents.
  • the process of the present invention comprises the steps of granulating the active agents cefpodoxime proxetil and clavulanic acid or its derivatives by conventional wet and/or dry granulation methods; or powdering cefpodoxime proxetil, clavulanic acid derivatives and other excipients after mixing them by dry blending method and compressing the pharmaceutical composition of the present invention in tablet form and optionally coating the tablets with a coating agent in the case that the product is developed in tablet form,
  • Another aspect of the present invention is that the formulation prepared according to said invention is used in the treatment of diseases related with infections caused by gram negative and gram positive bacteria.
  • the pharmaceutical composition prepared according to the present invention is used in the production of a medicament so as to be used in upper respiratory infections such as ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as pyelonephritis, cystitis and urethritis; skin or soft tissue infections such as froncle, pyoderma, impetigo; in the treatment and prophylaxis of gonorrhea and lyme diseases.
  • upper respiratory infections such as ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis
  • lower respiratory tract infections such as pyelonephritis, cystitis and urethritis
  • skin or soft tissue infections such as froncle, pyoderma, impetigo
  • in the treatment and prophylaxis of gonorrhea and lyme diseases in the production of a medicament so as to be used in upper respiratory infections such as
  • composition pertaining to the present invention can be prepared as described below, but not limited to the examples given.
  • EXAMPLE 1 Formulation and process for preparation of film tablet comprising cefpodoxime proxetil and sodium clavulanate
  • a process for preparation of pharmaceutical compositions of the present invention is composed of the steps of mixing and compressing cefpodoxime proxetil, the disintegrant and the diluent and then sieving them; adding the surfactant, potassium clavulanate, microcrystalline cellulose, disintegrant, glidant and lubricant into the granules obtained and mixing them; and then compressing tablets of the mixture obtained and coating the tablets with coating material.

Abstract

The present invention relates to pharmaceutical compositions comprising cefpod proxetil and clavulanic acid and/or its derivatives as the active agents.

Description

PHARMACEUTICAL COMPOSITION COMPRISING CEFPODOXIME PROXETIL
AND CLAVULANIC ACID
The present invention relates to pharmaceutical compositions comprising cefpodoxime proxetil and clavulanic acid and/or derivatives thereof as the active agents.
Background of the Invention
Cefpodoxime proxetil (formula I), chemical name of which is pivaloyloxymethyl 7-[2-(2- amino-thiazole-4-yl]-2-(syn)-methoxyimino-acetamido]-3-methoxymethyl-3-cefem-4- carboxylate, was first disclosed in the patent numbered EP0049118.
Formula 1
Clavulanic acid, on the other hand, is a beta-lactamase inhibitor illustrated in Formula 2.
Formula 2
Clavulanic acid and derivatives thereof (for instance its salts such as potassium clavulanate) are known as the beta-lactamase inhibitors which withstand the beta-lactamase-originated resistance mechanism by suppressing the activity of beta-lactamase enzymes.
The patent numbered EP0593573 comprises a formulation relating to suspension forms of beta-lactam antibiotics and beta lactamase inhibitors. However, suspension forms are not preferred much as they have the potential of high and/or uncontrolled dose intake; there appear problems in their physical and chemical stability; they have high manufacture costs and they cause problems in use and carrying.
To this end, the inventors have aimed to develop stable oral pharmaceutical formulations which comprise cefpodoxime proxetil and clavulanic acid derivatives together and eliminate the low solubility and gelling problems of cefpodoxime.
Description of the Invention:
The present invention relates to stable pharmaceutical compositions with good solubility characteristics in which cefpodoxime proxetil and clavulanic acid derivatives are formulated together. Said pharmaceutical composition is characterized by comprising 20% diluent at maximum in addition to cefpodoxim proxetil and clavulanic acid derivatives. It has surprisingly been seen that solid dosage forms which comprise the active agent cefpodoxime proxetil having rather low water solubility and are formulated by the formulation of the present invention have better solubility.
In an aspect, the pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid derivatives in combination comprises a diluent in the range of 20% or less, preferably in the range of 2-15%, more preferably in the range of 4-8%.
Cefpodoxime proxetil that can be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free base form and/or a combination thereof.
Clavulanic acid that can be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free base form and/or a combination thereof. Potassium clavulanate is preferably used in the present invention.
In addition to cefpodoxime proxetil, the formulation of the present invention can comprise various excipients such as, but not limited to, glidants, lubricants, disintegrants, diluents, surfactants and optionally coating agents.
The diluent that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof. Preferably, starch is used as the diluent in the pharmaceutical composition of the present invention.
In another aspect, it has been found that it has a positive effect on the dissolution of the formulation when the amount of the diluent used in the formulation of the present invention is less than 20%, preferably in the range of 2-15%, more preferably in the range of 4-8%.
The inventors have found that the ratio of cefpodoxime proxetil to the diluent is a factor affecting the dissolution of formulations comprising cefpodoxime proxetil and clavulanic acid or its derivatives. According to this, dissolution tests indicated that dissolution of cefpodoxime proxetil is at the desired level in the case that the ratio of cefpodoxime proxetil to the diluent is in the range of 10:1 to 1 :1, preferably in the range of 8:1 to 2:1, more preferably in the range of 6: 1 to 4: 1.
According to this, another aspect of the present invention is pharmaceutical compositions comprising cefpodoxime proxetil and clavulanic acid in which the ratio of cefpodoxime proxetil to the diluent is in the range of 10:1 to 1 :1, preferably in the range of 8:1 to 2:1, more preferably in the range of 6: 1 to 4: 1.
The glidant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or combinations thereof. Preferably, silicon dioxide or talc or a combination thereof is used as the glidant in the pharmaceutical composition of the present invention.
The inventors have found that use of a combination composed of talc and silicon dioxide yields more successful results in preventing antistatic adhesion. As a result of the studies they conducted, they have found that successful results are obtained in the case that the ratio of talc to silicon dioxide is in the range of 5:1 to 1:5, preferably in the range of 3:1 to 1 :3, more preferably 1:1.
According to this, another aspect of the present invention is use of a composition composed of talc and silicon dioxide as the glidant. According to another aspect, the present invention is pharmaceutical compositions comprising cefpodoxime proxetil and clavulanic acid or its derivatives which comprise a glidant composition wherein the ratio of talc to silicon dioxide is in the range of 5:1 to 1 :5, preferably in the range of 3 : 1 to 1 :3, more preferably 1 :1.
In the studies they conducted, the inventors have found that adhesion cannot be decently prevented in the case that each component of the glidant composition is used less than 0,6% in proportion to unit dose weight.
According to this, another aspect of the present invention is pharmaceutical compositions comprising cefpodoxime proxetil and clavulanic acid or its derivatives which include 0,6% talc and/or silicon dioxide at minimum in proportion to unit dose weight.
The lubricant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyoxyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or combinations thereof. Preferably, magnesium stearate is used as the lubricant in the pharmaceutical composition of the present invention.
The disintegrant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose calcium, carboxymethyl cellululose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropylcellulose, methyl cellulose, povidone, magnesium aluminum silicate, starch or combinations thereof. Preferably, croscarmellose sodium or microcrystalline cellulose or a combination thereof is used as the disintegrant in the formulation of the present invention.
The surfactant that can be used in the pharmaceutical composition of the present invention can be selected from, but not limited to, a group comprising docusate sodium, sorbitan esters, cetrimide and sodium lauryl sulfate. In the present invention, sodium lauryl sulfate is preferably used as the surfactant.
The pharmaceutical composition of the present invention can comprise 20-800 mg cefpodoxime proxetil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount. The pharmaceutical composition of the present invention can comprise 50-500 mg clavulanic acid or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
Clavulanic acid and its derivatives (e.g. potassium clavulanate) are extremely susceptible to moisture. To this respect, potassium clavulanate in the pharmaceutical composition is preferably used with a humectant in the ratio of 1 : 1.
One or more of the substances comprising silica; colloidal silica, for instance colloidal silica anhydrous, for example Aerosil® 200, magnesium trisilicate, cellulose powder, Cabosil®, magnesium oxide, calcium silicate, Syloid®, starch, microcrystalline cellulose, talc can be used as the humectant.
In the pharmaceutical composition of the present invention, potassium clavulanate is used with microcrystalline cellulose preferably in the ratio of 1 : 1.
The pharmaceutical composition of the present invention can comprise 5-60% cefpodoxime proxetil in proportion to total weight of unit dose or pharmaceutically acceptable solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms thereof.
The pharmaceutical composition of the present invention can comprise 5-50% clavulanic acid in proportion to total weight of unit dose or pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
The pharmaceutical composition of the present invention can comprise 5-60% cefpodoxime proxetil; 5-50% potassium clavulanate; 0,5-5% glidant; 0,1-5% lubricant; 0-25% disintegrant and/or disintegrants; 0,5-20% diluent; 0,1-5% surfactant and optionally coating agent of 1-5% of the core weight.
In another aspect, the pharmaceutical composition comprising cefpodoxim proxetil and clavulanic acid prepared according to the present invention can be in conventional tablet, film coated tablet, sachet or capsule form.
In another aspect, the present invention relates to processes for preparation of pharmaceutical compositions comprising pharmaceutically acceptable excipients in addition to cefpodoxime proxetil and clavulanic acid or its derivatives as the active agents. According to this, the process of the present invention comprises the steps of granulating the active agents cefpodoxime proxetil and clavulanic acid or its derivatives by conventional wet and/or dry granulation methods; or powdering cefpodoxime proxetil, clavulanic acid derivatives and other excipients after mixing them by dry blending method and compressing the pharmaceutical composition of the present invention in tablet form and optionally coating the tablets with a coating agent in the case that the product is developed in tablet form,
- filling the pharmaceutical composition of the present invention in capsules in the case that the product is developed in tablet form,
- filling the pharmaceutical composition of the present invention in packs in the case that the product is developed in sachet form.
Another aspect of the present invention is that the formulation prepared according to said invention is used in the treatment of diseases related with infections caused by gram negative and gram positive bacteria.
According to another aspect of the present invention, the pharmaceutical composition prepared according to the present invention is used in the production of a medicament so as to be used in upper respiratory infections such as ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as pyelonephritis, cystitis and urethritis; skin or soft tissue infections such as froncle, pyoderma, impetigo; in the treatment and prophylaxis of gonorrhea and lyme diseases.
The pharmaceutical composition pertaining to the present invention can be prepared as described below, but not limited to the examples given.
EXAMPLE 1: Formulation and process for preparation of film tablet comprising cefpodoxime proxetil and sodium clavulanate
According to this, a process for preparation of pharmaceutical compositions of the present invention is composed of the steps of mixing and compressing cefpodoxime proxetil, the disintegrant and the diluent and then sieving them; adding the surfactant, potassium clavulanate, microcrystalline cellulose, disintegrant, glidant and lubricant into the granules obtained and mixing them; and then compressing tablets of the mixture obtained and coating the tablets with coating material.

Claims

CLAIMS:
1. A pharmaceutical composition composed of a combination of cefpodoxime proxetil and clavulanic acid derivatives. wherein said composition comprises less than 20% diluent.
2. The pharmaceutical composition according to claim 1, wherein the amount of the diluent comprised in said composition is in the range of 2-15%.
3. The pharmaceutical composition according to claim 2, wherein the amount of the diluent comprised in said composition is in the range of 4-8%.
4. The pharmaceutical composition according to claim 1, wherein cefpodoxime proxetil comprised in said composition can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or combinations thereof.
5. The pharmaceutical composition according to claim 1, wherein clavulanic acid comprised in said composition can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or combinations thereof.
6. The pharmaceutical composition according to claim 5, wherein potassium clavulanate is preferably used in said composition.
7. The pharmaceutical composition according to claim 1, wherein said composition can comprise one or more excipients such as glidant, lubricant, disintegrant, diluent, surfactant and optionally coating agents in addition to cefpodoxime proxetil and potassium clavulanate.
8. The pharmaceutical composition according to claim 7, wherein the diluent can be selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
9. The pharmaceutical composition according to claim 8, wherein preferably starch is used in said composition.
10. The pharmaceutical composition according to claim 1, wherein the ratio of cefpodoxime proxetil to the diluent is in the range of 10: 1 to 1 : 1.
11. The pharmaceutical composition according to claim 10, wherein the ratio of cefpodoxime proxetil to the diluent is in the range of 8: 1 to 2: 1.
12. The pharmaceutical composition according to claim 11, wherein the ratio of cefpodoxime proxetil to the diluent is in the range of 6: 1 to 4: 1.
13. The pharmaceutical composition according to claim 7, wherein the glidant can be selected from a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or combinations thereof.
14. The pharmaceutical composition according to claim 7, wherein silicon dioxide or talc or a mixture composed of combination thereof is preferably used in said composition.
15. The pharmaceutical composition according to claim 14, wherein the ratio of talc to silicon dioxide is in the range of 5:1 to 1:5.
16. The pharmaceutical composition according to claim 15, wherein the ratio of talc to silicon dioxide is in the range of 3:1 to 1:3.
17. The pharmaceutical composition according to claim 16, wherein the ratio of talc to silicon dioxide is 1:1.
18. The pharmaceutical composition according to claim 14, wherein the amount of each component in glidant mixture is at least 0,6% of unit dose amount.
19. The pharmaceutical composition according to claim 7, wherein the lubricant can be selected from a group comprising calcium stearate, magnesium stearate, polyoxyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or combinations thereof.
20. The pharmaceutical composition according to claim 8, wherein magnesium stearate is preferably used as the lubricant in said formulation.
21. The pharmaceutical composition according to claim 7, wherein the disintegrant can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethyl cellululose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropylcellulose, methyl cellulose, povidone, magnesium aluminum silicate, starch or combinations thereof.
22. The pharmaceutical composition according to claim 7, wherein the surfactant can be selected from a group comprising docusate sodium, sorbitan esters, cetrimide and sodium lauryl sulfate.
23. The pharmaceutical composition according to claim 1, wherein said composition can comprise 20-800 mg cefpodoxime proxetil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
24. The pharmaceutical composition according to claim 1 , wherein said composition can comprise 50-500 mg clavulanic acid or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
25. The pharmaceutical composition according to claim 1, wherein clavulanic acid or its derivative is preferably used with a humectant in the ratio of 1 : 1.
26. The pharmaceutical composition according to claim 25, wherein the humectant to be used with clavulanic acid can be selected from a group comprising silica, colloidal silicon dioxide, magnesium trisilicate, cellulose powder, magnesium oxide, calcium silicate, starch, talc or microcrystalline cellulose.
27. The pharmaceutical composition according to claim 26, wherein the humectant to be used with clavulanic acid or its derivatives is preferably microcrystalline cellulose.
28. The pharmaceutical composition according to claim 1, wherein said composition comprises 5-60% cefpodoxime proxetil or pharmaceutically acceptable solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms thereof.
29. The pharmaceutical composition according to claim 1 , wherein said composition comprises 5-50% clavulanic acid or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
30. The pharmaceutical composition according to claim 1, wherein said composition comprises 5-60% cefpodoxime proxetil; 5-50% potassium clavulanate; 0,5-5% glidant; 0,1-5% lubricant; 0-25% disintegrant and/or disintegrants; 0,5-20% diluent; 0,1-5% surfactant in proportion to total unit dose amount and optionally coating agent of 1-5%) of the core weight.
31. The pharmaceutical composition according to claim 1 , wherein said composition can be used in conventional tablet, film coated tablet, sachet or capsule.
32. A process for preparation of the pharmaceutical composition claimed in any one of preceding claims, wherein said process is composed of the steps of granulating the active agents cefpodoxime proxetil and clavulanic acid or its derivatives by conventional wet and/or dry granulation methods; or powdering cefpodoxime proxetil, clavulanic acid and other excipients after mixing them by dry blending method.
33. The pharmaceutical composition according to claim 1 , wherein said composition is used in the treatment of diseases related with infections caused by gram negative and gram positive bacteria.
EP11790098.5A 2010-06-03 2011-06-02 Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid Withdrawn EP2575812A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201004466 2010-06-03
PCT/TR2011/000144 WO2011152805A2 (en) 2010-06-03 2011-06-02 Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid

Publications (1)

Publication Number Publication Date
EP2575812A2 true EP2575812A2 (en) 2013-04-10

Family

ID=44534579

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11738841.3A Active EP2575811B1 (en) 2010-06-03 2011-06-02 Pharmaceutical formulation comprising cefpodoxime proxetil and clavulanic acid
EP11790098.5A Withdrawn EP2575812A2 (en) 2010-06-03 2011-06-02 Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11738841.3A Active EP2575811B1 (en) 2010-06-03 2011-06-02 Pharmaceutical formulation comprising cefpodoxime proxetil and clavulanic acid

Country Status (2)

Country Link
EP (2) EP2575811B1 (en)
WO (2) WO2011152807A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151517A1 (en) * 2012-04-04 2013-10-10 Mahmut Bilgic Tablet formulations comprising cefpodoxime proxetil and clavulanic acid
WO2014123500A1 (en) * 2013-02-11 2014-08-14 Bilgiç Mahmut Pharmaceutical formulations comprising cefpodoxime proxetil and clavulanic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
GB9413542D0 (en) * 1994-07-05 1994-08-24 Smithkline Beecham Plc Pharmaceutical formulations
US6414142B1 (en) 1996-06-13 2002-07-02 Smithkline Beecham Corporation Process for preparing potassium clavulanate
CN1505515A (en) * 2001-02-27 2004-06-16 ʵ Oral pharmaceutical composition of cefpodoxime proxetil
AU2005204017B2 (en) * 2004-01-06 2008-01-31 Panacea Biotec Ltd. Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
WO2007086012A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation of cefpodoxime, clavulanic acid and linezolid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2011152805A2 *

Also Published As

Publication number Publication date
WO2011152805A3 (en) 2012-04-05
EP2575811A1 (en) 2013-04-10
WO2011152807A1 (en) 2011-12-08
WO2011152805A2 (en) 2011-12-08
EP2575811B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
EP2528594B1 (en) Effervescent formulations comprising second generation cephalosporin
EP2568959A2 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012060788A1 (en) Formulations of cephalosporins with controlled moisture content
WO2011142730A1 (en) Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound
WO2012060786A2 (en) Cefpodoxime proxetil formulations comprising viscosity agent
EP2566449B1 (en) Pharmaceutical compositions comprising ceftibuten
WO2011152805A2 (en) Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid
EP2515850B1 (en) Pharmaceutical compositions comprising cefdinir as an active agent
US20130129791A1 (en) Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
EP2833874A1 (en) Capsule formulations comprising ceftibuten
WO2012026907A2 (en) Cefpodoxime proxetil formulations
EP2575777A1 (en) Formulation comprising cefpodoxime proxetil and clavulanic acid
WO2011129792A1 (en) Water dispersible formulations comprising cefpodoxime proxetil
WO2011093828A2 (en) Solid dosage forms comprising cefprozil
WO2012060787A1 (en) Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium
WO2012060791A2 (en) Production method for pharmaceutical compositions comprising cefdinir
EP2833873A1 (en) Film tablet formulations comprising cefuroxime axetil and clavulanic acid
WO2012060792A1 (en) Pharmaceutical compositions comprising minimum 6 % of disintegrants by weight
WO2014123500A1 (en) Pharmaceutical formulations comprising cefpodoxime proxetil and clavulanic acid
WO2012060793A2 (en) Process for the preparation of cefdinir formulations
JP2007297348A (en) Tablet comprising ebastine
EP2663289A2 (en) Cefpodoxime proxetil formulations comprising taste regulating agent
EP2833872A1 (en) Tablet formulations comprising cefpodoxime proxetil and clavulanic acid
WO2012078121A2 (en) Solid oral dosage form comprising cefdinir
WO2014126541A1 (en) Pharmaceutical compositions used in treating bacterial infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121231

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20151130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180103